Forma Therapeutics Inc

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. The company leverages a sophisticated drug discovery engine that combines biology insight with chemistry expertise to target challenging pathways such as protein-protein interactions, epigenetics, and tumor metabolism. Following its acquisition by Novo Nordisk in 2022, the company has become a key component of Novo Nordisk's expansion into the rare blood disorder space. Its lead program, etavopivat, is a selective pyruvate kinase-R (PKR) activator designed to improve red blood cell health and address the underlying causes of sickle cell disease and thalassemia. The company also maintains a legacy of high-value oncology assets, many of which have been out-licensed to partners like Rigel Pharmaceuticals and Pathos AI.